WVE - WaVe Life Sciences Ltd Stock Price, Fair Value and News

6.25USD+0.35 (+5.93%)Delayed

Market Summary

USD6.25+0.35

Delayed

5.93%

WVE Alerts

Losses in recent quarter

WVE Stock Price

View Fullscreen

WVE RSI Chart

WVE Valuation

Market Cap

765.4M

Price/Earnings (Trailing)

-12.41

Price/Sales (Trailing)

6.78

EV/EBITDA

-10.19

Price/Free Cashflow

-5.49

WVE Price/Sales (Trailing)

WVE Profitability

EBT Margin

-55.21%

Return on Equity

-242.88%

Return on Assets

-26.21%

Free Cashflow Yield

-18.22%

WVE Fundamentals

WVE Revenue

Revenue (TTM)

112.9M

Rev. Growth (Yr)

2.2K%

Rev. Growth (Qtr)

-40.96%

WVE Earnings

Earnings (TTM)

-61.7M

Earnings Growth (Yr)

-15.15%

Earnings Growth (Qtr)

-94.13%

Breaking Down WVE Revenue

Last 7 days

11.2%

Last 30 days

30.5%

Last 90 days

59.9%

Trailing 12 Months

75.6%

How does WVE drawdown profile look like?

WVE Financial Health

Current Ratio

1.19

WVE Investor Care

Shares Dilution (1Y)

24.49%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	112.9M	0	0	0
2023	14.8M	36.6M	85.5M	113.3M
2022	42.7M	40.3M	4.2M	3.6M
2021	0	18.7M	52.1M	50.4M
2020	17.1M	12.5M	13.0M	20.1M
2019	16.0M	18.8M	17.2M	16.0M
2018	4.9M	8.7M	11.9M	14.4M
2017	1.9M	2.5M	3.5M	3.9M
2016	0	543.0K	809.0K	1.5M
2015	0	0	0	152.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of WaVe Life Sciences Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	moran kyle	sold	-96,421	6.169	-15,630	chief financial officer
Dec 11, 2023	ra capital management, l.p.	bought	5,000,000	5.00	1,000,000	-
Dec 07, 2023	gsk plc	bought	16,500,000	5.00	3,300,000	-
Aug 23, 2023	moran kyle	sold	-176,119	4.752	-37,062	chief financial officer
Feb 16, 2023	bolno paul	sold	-118,776	4.04	-29,400	president and ceo
Feb 16, 2023	vargeese chandra	sold	-41,303	4.03	-10,249	see remarks
Feb 16, 2023	francis chris	sold	-41,339	4.03	-10,258	see remarks
Feb 16, 2023	moran kyle	sold	-39,305	4.04	-9,729	chief financial officer
Jun 16, 2022	ra capital management, l.p.	bought	20,382,100	2.15	9,480,050	-

Which funds bought or sold WVE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	added	34.71	9,810,140	24,997,100	0.64%
May 17, 2024	Ikarian Capital, LLC	new	-	3,640,840	3,640,840	0.40%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	0.02	88,187	485,425	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-53.00	-170,806	230,356	-%
May 15, 2024	Point72 (DIFC) Ltd	new	-	55,349	55,349	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	217	7,493,080	10,091,700	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	531,237	531,237	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	1,470	2,437,150	2,571,190	0.01%
May 15, 2024	Cubist Systematic Strategies, LLC	added	27,315	421,618	422,881	-%
May 15, 2024	Woodline Partners LP	reduced	-31.84	-1,175,480	5,851,900	0.05%

Are Funds Buying or Selling WVE?

Are funds buying WVE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own WVE

No. of Funds

WVE Alerts

Losses in recent quarter

Unveiling WaVe Life Sciences Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	maverick capital ltd	6.9%	8,447,804	SC 13G/A
Feb 14, 2024	683 capital management, llc	4.7%	5,600,000	SC 13G/A
Feb 13, 2024	bb biotech ag	3.7%	4,494,458	SC 13G/A
Feb 12, 2024	m28 capital management lp	6.0%	7,373,413	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	5.03%	5,987,730	SC 13G/A
Feb 06, 2024	gsk plc	11.5%	13,983,761	SC 13G/A
Feb 14, 2023	683 capital management, llc	6.9%	6e+06	SC 13G/A
Feb 14, 2023	maverick capital ltd	8.2%	7,097,664	SC 13G/A
Feb 14, 2023	bb biotech ag	5.2%	4,494,458	SC 13G/A
Feb 10, 2023	m28 capital management lp	6.8%	5,903,405	SC 13G/A

Recent SEC filings of WaVe Life Sciences Ltd

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to WaVe Life Sciences Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

WaVe Life Sciences Ltd News

Latest updates

WaVe Life Sciences Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-56.8%	12,538,000	29,056,000	49,214,000	22,106,000	12,929,000	1,239,000	285,000	375,000	1,750,000	1,765,000	36,423,000	2,776,000	9,439,000	3,450,000	3,027,000	4,161,000	2,400,000	2,929,000	7,628,000	3,026,000	3,620,000
Operating Expenses	-1.6%	46,996,000	47,738,000	44,770,000	45,579,000	43,214,000	44,802,000	39,184,000	42,539,000	39,844,000	37,875,000	44,030,000	42,604,000	39,752,000	37,865,000	41,683,000	54,154,000	62,933,000	57,108,000	53,245,000	51,014,000	52,563,000
S&GA Expenses	-100.0%	-	13,664,000	13,128,000	12,265,000	12,235,000	13,724,000	11,609,000	12,806,000	12,374,000	12,114,000	12,944,000	10,969,000	9,719,000	9,590,000	10,205,000	12,996,000	13,805,000	12,523,000	11,640,000	10,901,000	12,754,000
R&D Expenses	-1.8%	33,447,000	34,074,000	31,642,000	33,314,000	30,979,000	31,078,000	27,575,000	29,733,000	27,470,000	25,761,000	31,086,000	31,635,000	30,033,000	28,275,000	31,478,000	41,158,000	49,128,000	44,585,000	41,605,000	40,113,000	39,809,000
EBITDA Margin	-8.2%	-0.51	-0.47	-0.93	-3.41	-9.74	-42.35	-35.02	-2.81	-2.59	-2.28	-2.10	-7.28	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-677,000	-	-	681,000	-	-	-	-204,000	-	-	-841,000	-	-	-	-	-	-	-	-117,000
Earnings Before Taxes	-94.1%	-31,558,000	-16,256,000	6,575,000	-21,104,000	-27,405,000	-43,028,000	-39,004,000	-41,296,000	-37,814,000	-34,989,000	-6,230,000	-38,766,000	-29,630,000	-33,100,000	-40,528,000	-47,493,000	-56,770,000	-50,726,000	-41,942,000	-44,200,000	-37,990,000
EBT Margin	-7.5%	-0.55	-0.51	-0.99	-3.57	-10.17	-44.16	-36.67	-2.98	-2.76	-2.43	-2.25	-7.70	-	-	-	-	-	-	-	-	-
Net Income	-94.1%	-31,558,000	-16,256,000	7,252,000	-21,104,000	-27,405,000	-43,709,000	-39,004,000	-41,296,000	-37,814,000	-34,785,000	-6,230,000	-38,766,000	-28,789,000	-33,100,000	-40,528,000	-47,493,000	-56,770,000	-50,726,000	-41,942,000	-44,200,000	-37,887,000
Net Income Margin	-7.6%	-0.55	-0.51	-0.99	-3.59	-10.21	-44.35	-36.62	-2.98	-2.75	-2.43	-2.23	-7.66	-	-	-	-	-	-	-	-	-
Free Cashflow	-0.8%	-33,849,000	-33,595,000	-34,655,000	-37,329,000	85,033,000	-33,644,000	-26,103,000	-29,314,000	-40,081,000	-7,048,000	-28,282,000	-9,740,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-14.4%	235	275	200	230	267	146	182	213	167	207	201	206	243	279	310	204	239	284	347	386	431
Current Assets	-16.4%	197	235	159	185	220	99.00	131	160	124	163	158	159	195	230	258	147	150	185	250	290	315
Cash Equivalents	-9.7%	181	200	140	173	208	88.00	97.00	123	62.00	151	124	144	149	184	216	216	121	147	209	253	288
Net PPE	-5.1%	12.00	13.00	14.00	15.00	16.00	17.00	19.00	20.00	21.00	22.00	24.00	26.00	27.00	29.00	31.00	33.00	35.00	36.00	37.00	38.00	40.00
Liabilities	-11.2%	202	227	233	274	294	184	178	174	160	167	163	177	182	189	194	201	210	213	225	217	226
Current Liabilities	-11.0%	166	186	100	140	133	72.00	64.00	64.00	58.00	64.00	32.00	47.00	49.00	121	110	110	119	118	133	124	132
Shareholder's Equity	-35.9%	25.00	40.00	-	-	-34.71	-45.09	-	31.00	-	32.00	30.00	22.00	53.00	83.00	108	-	21.00	64.00	115	160	197
Retained Earnings	-3.1%	-1,056	-1,024	-1,008	-1,015	-994	-967	-923	-884	-843	-805	-770	-764	-725	-683	-654	-621	-580	-533	-476	-425	-383
Additional Paid-In Capital	2.2%	132	129	127	125	122	119	117	113	92.00	88.00	84.00	78.00	76.00	72.00	68.00	65.00	61.00	57.00	52.00	47.00	42.00
Accumulated Depreciation	2.3%	44.00	43.00	42.00	40.00	39.00	38.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	2.6%	122	119	99.00	99.00	98.00	87.00	74.00	64.00	61.00	60.00	51.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	259	-	-	-	205	-	-	-	270	-	-	-	267	-	-	-	631	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-0.6%	-33,432	-33,239	-34,457	-37,257	85,522	-33,440	-25,646	-28,822	-39,873	-7,033	-28,184	-9,401	-44,375	-31,415	-20,172	-38,145	-26,250	-61,240	-43,681	-32,929	-50,381
Share Based Compensation	-100.0%	-	2,352	2,284	2,409	2,750	2,907	3,366	6,950	3,971	3,726	5,896	2,722	4,063	3,219	3,284	3,794	3,999	4,987	5,020	5,157	4,345
Cashflow From Investing	-17.1%	-417	-356	-198	-72.00	-489	24,840	-501	24,614	-50,208	-15.00	-98.00	-339	-108	-557	-65.00	-136	-580	-1,346	-465	-1,599	-508
Cashflow From Financing	-84.6%	14,510	93,962	1,670	1,849	35,053	55.00	17.00	65,800	1,316	33,793	8,349	5,045	8,641	19.00	142,523	11,382	614	757	253	-157	163,546

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

WVE Income Statement

2024-03-31

Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 12,538,000	$ 12,929,000
Operating expenses:
Research and development	33,447,000	30,979,000
General and administrative	13,549,000	12,235,000
Total operating expenses	46,996,000	43,214,000
Loss from operations	(34,458,000)	(30,285,000)
Other income, net:
Dividend income and interest income	2,535,000	1,873,000
Other income, net	365,000	1,007,000
Total other income, net	2,900,000	2,880,000
Loss before income taxes	(31,558,000)	(27,405,000)
Income tax benefit (provision)	0	0
Net loss	$ (31,558,000)	$ (27,405,000)
Net loss per share attributable to ordinary shareholders basic	$ (0.24)	$ (0.27)
Net loss per share attributable to ordinary shareholders diluted	$ (0.24)	$ (0.27)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic	129,271,678	102,056,712
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted	129,271,678	102,056,712
Other comprehensive loss:
Net Income (Loss)	$ (31,558,000)	$ (27,405,000)
Foreign currency translation	(74,000)	(21,000)
Comprehensive loss	$ (31,632,000)	$ (27,426,000)

WVE Balance Sheet

2024-03-31

Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 180,922	$ 200,351
Accounts receivable	0	21,086
Prepaid expenses	11,139	9,912
Other current assets	4,706	4,024
Total current assets	196,767	235,373
Long-term assets:
Property and equipment, net of accumulated depreciation of $43,687 and $42,709 as of March 31, 2024 and December 31, 2023, respectively	12,418	13,084
Operating lease right-of-use assets	21,502	22,637
Restricted cash	3,715	3,699
Other assets	868	156
Total long-term assets	38,503	39,576
Total assets	235,270	274,949
Current liabilities:
Accounts payable	11,730	12,839
Accrued expenses and other current liabilities	6,621	16,828
Current portion of deferred revenue	140,586	150,059
Current portion of operating lease liability	6,936	6,714
Total current liabilities	165,873	186,440
Long-term liabilities:
Deferred revenue, net of current portion	12,536	15,601
Operating lease liability, net of current portion	23,598	25,404
Total long-term liabilities	36,134	41,005
Total liabilities	202,007	227,445
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at March 31, 2024 and December 31, 2023	7,874	7,874
Shareholders' equity:
Ordinary shares, no par value; 122,321,384 and 119,162,234 shares issued and outstanding at March 31, 2024 and December 31,2023, respectively	949,877	935,367
Additional paid-in capital	132,118	129,237
Accumulated other comprehensive loss	(198)	(124)
Accumulated deficit	(1,056,408)	(1,024,850)
Total shareholders' equity	25,389	39,630
Total liabilities, Series A preferred shares and shareholders' equity	$ 235,270	$ 274,949

About WaVe Life Sciences Ltd

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

CEO	Dr. Paul B. Bolno M.B.A., M.D., MBA
WEBSITE	wavelifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	250

WaVe Life Sciences Ltd Frequently Asked Questions

What is the ticker symbol for WaVe Life Sciences Ltd? What does WVE stand for in stocks?

WVE is the stock ticker symbol of WaVe Life Sciences Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of WaVe Life Sciences Ltd (WVE)?

As of Fri May 17 2024, market cap of WaVe Life Sciences Ltd is 765.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WVE stock?

You can check WVE's fair value in chart for subscribers.

What is the fair value of WVE stock?

You can check WVE's fair value in chart for subscribers. The fair value of WaVe Life Sciences Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of WaVe Life Sciences Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WVE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is WaVe Life Sciences Ltd a good stock to buy?

The fair value guage provides a quick view whether WVE is over valued or under valued. Whether WaVe Life Sciences Ltd is cheap or expensive depends on the assumptions which impact WaVe Life Sciences Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WVE.

What is WaVe Life Sciences Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, WVE's PE ratio (Price to Earnings) is -12.41 and Price to Sales (PS) ratio is 6.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WVE PE ratio will change depending on the future growth rate expectations of investors.